Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship rights. New client data released today by global leaders in citizenship and residence planning, Henley & Partners, confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term

Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship rights. New client data released today by global leaders in citizenship and residence planning, Henley & Partners, confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy. BERGISCH GLADBACH, Germany, Dec. 07, 2025

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy. BERGISCH GLADBACH, Germany, Dec. 07, 2025

Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer Leave a reply Cochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26-metre electric TRAnsverse (“TRAnsverse 2600e”) tugs to be constructed in India for Svitzer’s global fleet renewal and growth plans.  Svitzer Nobbys TRAnsverse 3200 Pictured: A TRAnsverse 3200 tug. Svitzer’s agreement with Cochin Shipyard covers the related TRAnsverse 2600e electric tugs The agreement confirms a Letter of Intent signed in October 2025 at India Maritime Week and marks the move from intent to a